|
Volume 16, Issue 3 (May 2014) 16, 401–406; 10.4103/1008-682X.123684
Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
Jingsong Zhang
Department of Genitourinary Oncology and Department of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Correspondence: Dr. J Zhang (jingsong.zhang@moffitt.org)
2014-2-25
| Abstract |
|
Recent phase I studies have reported single-agent activities of poly (ADP-ribose) polymerase (PARP) inhibitor in sporadic and in BRCA-mutant prostate cancers. Two of the most common genetic alterations in prostate cancer, ETS gene rearrangement and loss of PTEN, have been linked to increased sensitivity to PARP inhibitor in pre-clinical models. Emerging evidence also suggests that PARP1 plays an important role in mediating the transcriptional activities of androgen receptor and ETS gene rearrangement. In this article, the preclinical work and early-phase clinical trials in developing PARP inhibitor-based therapy as a new treatment paradigm for metastatic prostate cancer are reviewed.
Keywords: biomarker; PARP inhibitor; prostate cancer; therapy
Full Text |
PDF |
中文摘要 |
|
| |
| Browse: 3499 |
|
